LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Lista de Ações・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

11.49 0.7

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.96

Máximo

11.61

Indicadores-chave
By Trading Economics
Rendimento	227M
Vendas	139M
P/E Médio do Setor	4.302 49.888
Margem de lucro	163.843
Funcionários	1,796
EBITDA	1.3M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+47.37% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2B
Abertura anterior	10.79
Fecho anterior	11.49

Sentimento de Notícias

By Acuity

10%

90%

13 / 344 Ranking em Healthcare

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de jun. de 2026, 20:30 UTC

Ganhos

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 de jun. de 2026, 23:58 UTC

Conversa de Mercado

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 de jun. de 2026, 23:41 UTC

Conversa de Mercado

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 de jun. de 2026, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 de jun. de 2026, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 de jun. de 2026, 23:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 de jun. de 2026, 22:57 UTC

Conversa de Mercado

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 de jun. de 2026, 22:50 UTC

Conversa de Mercado

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 de jun. de 2026, 21:07 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de jun. de 2026, 21:07 UTC

Conversa de Mercado

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 de jun. de 2026, 21:00 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

2 de jun. de 2026, 20:46 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:38 UTC

Ganhos

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 de jun. de 2026, 20:21 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:12 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Product Rev $594M

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Loss $177M >PANW

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

47.37% parte superior

Previsão para 12 meses

Média 16.8 USD 47.37%

Máximo 20 USD

Mínimo 13.6 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Sentimento

By Acuity

13 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.